ReviewInternational journal of nanomedicine2014
Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes.
Review in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.European journal of endocrinology · 2017Trial
- Transdermal needle-free drug delivery approaches and activation mechanism.Materials today. Bio · 2026Review
- Once-Weekly Lonapegsomatropin Was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial.Hormone research in paediatrics · 2026Article
- Tracking the Effect of Phosvitin (PV) Concentration on the Skin Permeation of Somatotropin (STH) from Semi-Solid Hydrogel Formulations.Polymers · 2025Article
- Article
- One IV HEDGES DNA vector administration encoding hGLA or hGH produces durable hGLA and hGH serum lvels in immunocompetent mice.PloS one · 2025Article
- Preparation of RGD-modified liposomes encapsulated with shikonin and its targeted anti-melanoma effects.Frontiers in oncology · 2025Article
- Maleimide-Functionalized Liposomes: Prolonged Retention and Enhanced Efficacy of Doxorubicin in Breast Cancer with Low Systemic Toxicity.Molecules (Basel, Switzerland) · 2022Article
- Transdermal Co-Delivery of Urea and Recombinant Human Growth Hormone.Iranian journal of biotechnology · 2021Article
- Enhancement of The Stability of Human Growth Hormone by Using Tris(hydroxymethyl)aminomethane: Molecular Docking and Experimental Analysis.Cell journal · 2021Article
- Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.The Journal of clinical endocrinology and metabolism · 2020Review
- Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.Drug delivery and translational research · 2020Article
- Melanoma Peptide MHC Specific TCR Expressing T-Cell Membrane Camouflaged PLGA Nanoparticles for Treatment of Melanoma Skin Cancer.Frontiers in bioengineering and biotechnology · 2020Article
- Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins.Pharmaceutics · 2019Review
- Hydrogels For Peptide Hormones Delivery: Therapeutic And Tissue Engineering Applications.Drug design, development and therapy · 2019Review
- ZnScientific reports · 2018Article
- Bioprocess and downstream optimization of recombinant human growth hormone inResearch in pharmaceutical sciences · 2018Article
- Review
- Transdermal delivery of human growth hormone via laser-generated micropores.Drug delivery and translational research · 2018Article
- Structural Stability of Recombinant Human Growth Hormone (r-hGH) as a Function of Polymer Surface Properties.Pharmaceutical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the availability of recombinant human growth hormone (rhGH) enabled the application of human growth hormone both in clinical and research use in the 1980s, millions of patients were prescribed a daily injection of rhGH, but noncompliance rates were high. To address the problem of noncompliance, numerous studies have been carried out, involving: sustained-release preparations, prolonged half-life derivatives, new injectors that cause less pain, and other noninvasive delivery methods such as intranasal, pulmonary and transdermal deliveries. Some accomplishments have been made and launched already, such as the Nutropin Depot microsphere and injectors (Zomajet, Serojet, and NordiFlex). Here, we provide a review of the different technologies and illustrate the key points of these studies to achieve an improved rhGH product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.